TRE-515 Therapy Targets Multiple Pathways to Improve Treatment Efficacy Over Single-Agent Approaches Trethera Corporation, a Los Angeles-based clinical-stage biopharmaceutical company, is developing cancer treatments for orphan blood cancers with high unmet needs. […]
Targeted DiversiTy™ Therapy Promotes Surveillance and Destruction of Cancer Cells By Re-Educating Patients’ Own T Cells Geneius is an immuno-oncology company based in Natick, MA, that is focused on T-cell immunotherapies for […]
Light-Activated Intracellular Acidosis Therapy May Cause Cancer Cells to Undergo Rapid Apoptosis Vitanova Biomedical Inc., a San Antonio-based early-stage biotechnology company, is currently conducting pre-clinical trials on a proprietary Light-Activated Intracellular Acidosis […]
Blood-Filtering Device Treats Cancer By Removing Blocking Proteins Released By Cancer Cells Immunicom Inc., a San Diego-based immuno-oncology company, is developing a proprietary subtractive device-based technology platform as a novel approach to […]
Novocure is an oncology company working to develop a novel cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid […]
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. They currently have an innovative and […]
Altor BioScience is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and viral infections, based on its engineered cytokine technology platforms. It was formed in 2002 by Dr. […]
ImmunoCellular is a L.A.-based clinical stage company developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular’s pipeline includes: a Stem-to-T-cell research program, which engineers hematopoietic stem cells to generate […]
